The global Migraine Drugs Market size is expected to be valued at USD 13.34 billion by 2030, as per a new report by Grand View Research, Inc., exhibiting an 11.9% CAGR during the forecast period. The market is largely driven by factors such as a rise in disease prevalence, development of novel therapies, lifestyle changes, and hormonal medications.
Migraine is a debilitating neurological disease characterized by recurrent attacks of severe throbbing head pain that can last for more than three days. Migraine pain may get worse on movement, preventing the patient from carrying out normal, day-to-day activities. In about one-third of attacks, both sides of the head, face, or neck are affected.
Over the past five years, the global migraine drugs market has been relatively stagnant, with the market mainly dominated by usage of generic triptans and other off-label drugs. Majority of the currently prescribed drugs for both acute and preventative treatment are associated with poor efficacy and an unfavorable side-effect profile.
Launch of Amgen/ Novartisâ CGRP mAb Aimovig and Teva Pharmaâs Ajovy is the first step toward revolutionizing the treatment paradigm of migraine prevention. For drug manufacturers likely to enter the market by 2019, such as Eli Lilly, Alder BioPharma, and Biohaven Pharma, pricing will be a key differentiating factor as all CGRP-based therapies have a similar efficacy and safety profile.
List of Key Players in the Migraine Drugs Market
- AbbVie Inc.
- Amgen Inc.
- Teva Pharmaceutical Industries Ltd.
- GSK plc
- Eli Lilly and Company
- Pfizer Inc.
- Bausch Health Companies Inc.
- Gensco Pharma
- Impel Pharmaceuticals Inc.
- Tonix Medicines, Inc.
- Currax Pharmaceuticals LLC.
- Lundbeck
Request a free sample copy or view report summary: Migraine Drugs Market Report
Migraine Drugs Market Report Highlights
- Germany leads the European market, driven by rising disease prevalence, novel drug launches, and an increase in R&D activities
- The acute migraine treatment market will be supported by the rapid uptake of novel drug classes such as CGRP receptor antagonists and ditans currently under active investigation in multiple Phase II/III trials
- Biohavenâs rimegepant is expected to face competition from Allergan's ubrogepant, which has shown superior efficacy in Phase III trials compared to rimegepant
- Eli Lillyâs Phase III 5-HT1F receptor agonist Lasmiditan is expected to be a novel first-line non triptan acute treatment option for patients in whom triptans are contradicted
- Approximately 20% of patients seeking preventive treatment for migraine do not respond to available generic medications. Several biologics and small molecules drugs are undergoing active development to target high unmet needs in the preventive treatment segment
- Drugs with novel targets in early-phase development include AOBiome Therapeuticsâ AOB-203 (antibacterial), Winston Pharmaâs Dolorac (histamine H1 receptor antagonists), NeuroAxonsâ NXN-188 (a combination of NOS inhibitor and a triptan), and Biohavenâs BHV-3500 (gepant). These novel agents are under evaluation for both episodic and chronic migraine in multiple Phase I/II trials.
